Explore

Trendline Trendline
Merck Adjusts Acquisition Offer for Terns Pharmaceuticals After Leukemia Data Update

Merck Adjusts Acquisition Offer for Terns Pharmaceuticals After Leukemia Data Update

Merck Adjusts Acquisition Offer for Terns Pharmaceuticals After Leukemia Data Update
Trendline Trendline
Merck Co. Acquires Terns Pharmaceuticals for $6.7 Billion to Enhance Hematology Pipeline

Merck Co. Acquires Terns Pharmaceuticals for $6.7 Billion to Enhance Hematology Pipeline

Merck Co. Acquires Terns Pharmaceuticals for $6.7 Billion to Enhance Hematology Pipeline
Trendline Trendline
Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology

Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology

Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology
Trendline Trendline
Roche Expands Partnership with C4 Therapeutics, Commits Over $1 Billion for Cancer Therapy Development

Roche Expands Partnership with C4 Therapeutics, Commits Over $1 Billion for Cancer Therapy Development

Roche Expands Partnership with C4 Therapeutics, Commits Over $1 Billion for Cancer Therapy Development
Trendline Trendline
Phanes Therapeutics Expands Clinical Study of Spevatamig for Biliary Tract Cancer Treatment

Phanes Therapeutics Expands Clinical Study of Spevatamig for Biliary Tract Cancer Treatment

Phanes Therapeutics Expands Clinical Study of Spevatamig for Biliary Tract Cancer Treatment
Trendline Trendline
Gilead Sciences Shifts Focus to Integration After Series of Acquisitions

Gilead Sciences Shifts Focus to Integration After Series of Acquisitions

Gilead Sciences Shifts Focus to Integration After Series of Acquisitions
Trendline Trendline
Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline
Trendline Trendline
Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition

Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition

Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition
Trendline Trendline
Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities
Trendline Trendline
Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline
Trendline Trendline
Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition